Clinical trial
Trial Exploring Feasibility of Densification and Optimal Sequencing of…
NCT00256360 · Universitaire Ziekenhuizen KU Leuven, Other · Completed
Key facts
| NCT number | NCT00256360 |
|---|---|
| Title | Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer |
| Official title | A Randomized Phase II Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer |
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven, Other |
| Collaborators | St-Augustinus Wilrijk |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | dose dense with neulasta |
| Enrollment | 117 |
| Start date | Sep 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Nov 21, 2005 |
| Last update posted | Dec 9, 2014 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: